KROLL-ONTRACK
Kroll Ontrack , the leading provider of ediscovery and data recovery products and services, today announced it is adding kCura's Relativity to its ediscovery offering in Europe. As a Relativity Premium Hosting partner, Kroll Ontrack is now giving law firms and companies flexibility in their choice of document review tools, based on the needs of their projects.
Kroll Ontrack has successfully offered Relativity in the US since 2014 and has integrated proprietary, award-winning technology enhancements – including cost-saving nearline technology – into its Relativity offering to give clients greater control of their data and costs. This enhanced offering of Relativity is now available in the UK and will be deployed in other European countries too.
Tim Phillips, Managing Director of Kroll Ontrack International Legal Technologies said: “Kroll Ontrack is making it easier for both law firms and companies to choose a leading review tool best suited to their needs, either ediscovery.com Review or Relativity, based on workflow requirements, data analytics, user preferences and other features. Regardless of their choice, clients are supported by Kroll Ontrack’s global network of consulting experts who help clients leverage the most advanced technology features to gain better control over their overall data volumes and ediscovery spend.”
John Grancarich, vice president of product management, Kroll Ontrack said: “Each and every ediscovery project is unique, with different parameters and deadlines, requiring different technology functionality. The addition of Relativity to our ediscovery offering means our team is equipped with a flexible toolkit and the expertise to recommend the best approach to solve every customer challenge.”
Kroll Ontrack received the 2015 Relativity Innovation Award for Best Service Provider Solution for its integration of proprietary “nearline” technology – originally built to reduce data volumes and costs in ediscovery.com Review – into its offering of Relativity. Nearline technology empowers users to easily identify and set aside (or nearline) non-critical data on demand, and retrieve nearline data in a similar, on-demand manner, without reprocessing and with work product intact. As nearline storage is 50 percent less costly than active storage, organisations can significantly reduce data volumes and costs associated with ediscovery, while providing more efficient access to critical documents.
Tim Phillips continues: “Organisations are seeking ways to leverage technology to reduce the costs associated with ediscovery and reduce time spent reviewing documents. Our nearline technology addresses both. Over the last 12 months, nearly 100 clients have taken advantage of cost-saving nearline technology in ediscovery.com Review.”
Kroll Ontrack’s integration of this proprietary technology into Relativity directly addresses the market demand for innovative, cost-cutting technologies – regardless of review tool choice.
In addition to proprietary nearline technology in Relativity, Kroll Ontrack offers:
Certified Relativity Expertise: Kroll Ontrack’s experienced global Relativity team includes Relativity Experts, a Relativity Master, Relativity Certified Administrators, Relativity Infrastructure Specialists and Relativity Analytics Specialists. Kroll Ontrack professionals leverage the most advanced Relativity features to skilfully guide matters and recommend strategies to promote the best possible outcome.
Early Case Assessment (ECA) workflow: By allowing only text and metadata to be loaded into the Relativity platform, costs can be significantly reduced. The power and flexibility of Relativity’s search and analytics functionality can be used during ECA to gain early data insight and prioritise the most important data for earlier review.
Assisted Redaction: Sensitive information can be protected and the redaction process can be streamlined through an automated approach to identify and redact Personally Identifiable Information (PII), privileged or other pertinent information based on user-defined criteria.
Grancarich concludes: “With unprecedented user-driven control, our offering of Relativity is a powerful tool to help organisations manage the mounting data and costs associated with data analysis and review. By combining nearline technology, a customised ECA workflow and assisted redaction with our full team of certified Relativity experts and consultants, Kroll Ontrack delivers an efficient, accurate and cost-effective review.”
For more information about Relativity from Kroll Ontrack, visit: http://www.ediscovery.com/uk/solutions/relativity/
About Kroll Ontrack LLC
Kroll Ontrack provides technology-driven services and software to help legal, corporate and government entities as well as consumers manage, recover, search, analyse, and produce data efficiently and cost-effectively. In addition to its award-winning suite of software, Kroll Ontrack provides data recovery, data destruction, electronic discovery and document review services. For more information about Kroll Ontrack and its offerings please visit: http://www.ediscovery.com/uk and follow @KrollOntrackUK on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151209005565/en/
Contact:
Citigate Dewe Rogerson
Camilla Medd
Tel: +44 20 7282
1021
Email: camilla.medd@citigate.co.uk
or
Judith
Massey
Tel: +44 20 7282 2987
judith.massey@citigatedr.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 08:00:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 07:30:00 CEST | Press release
Solid Start to the Year SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including pr
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom